NASC (Nascent Pharma Holdings) Retained Earnings: $-113.93 Mil (As of Sep. 2024)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.02
View Full Analysis

What is Nascent Pharma Holdings Retained Earnings?

Nascent Pharma Holdings NASC -0.01% 12 Retained Earnings is $-113.93 Mil as of Sep. 2024. GuruFocus rates NASC with a GF Score™ of 12/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Nascent Pharma Holdings's retained earnings for the quarter that ended in Sep. 2024 was $-113.93 Mil.

Nascent Pharma Holdings's quarterly retained earnings declined from Mar. 2024 ($-107.48 Mil) to Jun. 2024 ($-110.67 Mil) and declined from Jun. 2024 ($-110.67 Mil) to Sep. 2024 ($-113.93 Mil).

Nascent Pharma Holdings's annual retained earnings declined from Dec. 2021 ($-77.77 Mil) to Dec. 2022 ($-92.69 Mil) and declined from Dec. 2022 ($-92.69 Mil) to Dec. 2023 ($-102.43 Mil).


Nascent Pharma Holdings  (OTCPK:NASC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Nascent Pharma Holdings Retained Earnings Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Retained Earnings Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.67 -65.60 -77.77 -92.69 -102.43

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.62 -102.43 -107.48 -110.67 -113.93
NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-113.93 Mil mean?
Nascent Pharma Holdings (NASC) has a Retained Earnings of $-113.93 Mil as of Sep. 2024. Retained earnings is the amount of net income not issued to shareholders. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Retained Earnings too high?
Nascent Pharma Holdings' current Retained Earnings is $-113.93 Mil. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Retained Earnings compare to ALID and CPMD?
Nascent Pharma Holdings' Retained Earnings of $-113.93 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Nascent Pharma Holdings and its competitors. Nascent Pharma Holdings's current Retained Earnings is $-113.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Retained Earnings of $-113.93 Mil. The current Retained Earnings is $-113.93 Mil. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Retained Earnings is $-113.93 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price